

Pfizer Oncology: Pursuing Scientific Breakthroughs for Patients With Hematologic Malignancies



Suneet Varma, MBA Global Oncology and US President, Pfizer Oncology



Dany Habr, MD Chief Medical Affairs Officer, Pfizer Oncology



Sriram Krishnaswami, PhD Vice President, Development Head, Multiple Myeloma, Pfizer Oncology

Date: Saturday, December 10 Time: 11:30 AM - 12:30 PM CT

OPTIONS TO JOIN LIVE OR VIRTUALLY

1. LIVE: Theater 7

New Orleans Ernest N. Morial Convention Center

Exhibit Hall (Halls G-J)

2. VIRTUALLY: #ASH22 Platform

AGENDA HIGHLIGHTS

Senior leaders from Pfizer will present:

- The vision for delivering innovations in oncology and commitment to addressing health care disparities
- Pfizer's heritage and research initiatives in hematologic malignancies with a focus on addressing unmet needs for patients with multiple myeloma through transformative science
- The complexity of multiple myeloma treatment and ongoing advancements in the treatment landscape

This meeting is organized and funded by Pfizer.

Not an official event of the 64th ASH Annual Meeting and Exposition. This presentation is not sponsored or endorsed by ASH. Not CME-accredited.